IN2014DN00101A - - Google Patents

Info

Publication number
IN2014DN00101A
IN2014DN00101A IN101DEN2014A IN2014DN00101A IN 2014DN00101 A IN2014DN00101 A IN 2014DN00101A IN 101DEN2014 A IN101DEN2014 A IN 101DEN2014A IN 2014DN00101 A IN2014DN00101 A IN 2014DN00101A
Authority
IN
India
Prior art keywords
dendrimer
macromolecules
pharmaceutically active
active agent
surface amino
Prior art date
Application number
Other languages
English (en)
Inventor
David Owen
Brian Devlin Kelly
Peter Karellas
Original Assignee
Starpharma Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Starpharma Pty Ltd filed Critical Starpharma Pty Ltd
Publication of IN2014DN00101A publication Critical patent/IN2014DN00101A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/40—Polyamides containing oxygen in the form of ether groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers
IN101DEN2014 2011-06-06 2012-06-06 IN2014DN00101A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161493886P 2011-06-06 2011-06-06
PCT/AU2012/000647 WO2012167309A1 (en) 2011-06-06 2012-06-06 Macromolecules

Publications (1)

Publication Number Publication Date
IN2014DN00101A true IN2014DN00101A (pt) 2015-05-15

Family

ID=47295262

Family Applications (1)

Application Number Title Priority Date Filing Date
IN101DEN2014 IN2014DN00101A (pt) 2011-06-06 2012-06-06

Country Status (19)

Country Link
US (2) US9744246B2 (pt)
EP (1) EP2729179B1 (pt)
JP (1) JP6158177B2 (pt)
KR (1) KR101941318B1 (pt)
CN (2) CN110124051B (pt)
AU (1) AU2012267200B2 (pt)
BR (1) BR112013031556B1 (pt)
CA (1) CA2837979C (pt)
DK (1) DK2729179T3 (pt)
ES (1) ES2834992T3 (pt)
HK (1) HK1198356A1 (pt)
HR (1) HRP20201998T1 (pt)
HU (1) HUE052285T2 (pt)
IN (1) IN2014DN00101A (pt)
LT (1) LT2729179T (pt)
PL (1) PL2729179T3 (pt)
PT (1) PT2729179T (pt)
SI (1) SI2729179T1 (pt)
WO (1) WO2012167309A1 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117164357A (zh) * 2023-01-03 2023-12-05 广东捷成科创电子股份有限公司 一种五元系大功率型压电陶瓷材料及其制备方法

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180326081A1 (en) * 2011-06-06 2018-11-15 Starpharma Pty Ltd Macromolecules
EP2996726A1 (fr) * 2013-05-16 2016-03-23 Université de Strasbourg Composés dendritiques comprenant un agent chélatant, fluorochrome ou agent de reconnaissance, compositions les comprenant et leurs utilisations
US20160220689A1 (en) * 2013-09-10 2016-08-04 Starpharma Pty Ltd. Macromolecules of dendrimer-platinum conjugates
US10730999B2 (en) 2014-06-06 2020-08-04 Starpharma Pty Ltd Dendrimer-drug conjugates
WO2017025057A1 (en) 2015-08-11 2017-02-16 Coherent Biopharma Multi-ligand drug conjugates and uses thereof
CN106554330B (zh) * 2015-09-26 2019-07-05 南京友怡医药科技有限公司 水溶性多西他赛抗癌药物化合物及其制备方法和应用
CN106554329B (zh) * 2015-09-26 2019-07-05 南京友怡医药科技有限公司 水溶性紫杉醇抗癌药物化合物及其制备方法和应用
WO2017068051A1 (en) * 2015-10-21 2017-04-27 Lek Pharmaceuticals D.D. Peg-based dendron and process for producing the same
WO2017135893A1 (en) * 2016-02-05 2017-08-10 Nipsea Technologies Pte Ltd Aqueous dendritic amine coatings
US20190142953A1 (en) * 2016-05-10 2019-05-16 Massachusetts Institute Of Technology Dendrimer-Drug Conjugates, Hydrogel Compositions, and Methods
JOP20190191A1 (ar) 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية
CA3095644A1 (en) * 2018-03-29 2019-10-03 Nof Corporation Degradable polyethylene glycol conjugate
JP2021529818A (ja) * 2018-07-19 2021-11-04 スターファーマ ピーティーワイ エルティーディー 治療用デンドリマー
TW202021575A (zh) * 2018-08-17 2020-06-16 瑞典商阿斯特捷利康公司 樹枝狀體配製物
TWI831817B (zh) * 2018-08-17 2024-02-11 瑞典商阿斯特捷利康公司 治療癌症之方法
KR20210094541A (ko) * 2018-11-20 2021-07-29 스타파마 피티와이 리미티드 치료 덴드리머
JP2022513630A (ja) * 2018-11-29 2022-02-09 スターファーマ ピーティーワイ エルティーディー 治療および画像化のためのデンドリマー
KR20220052960A (ko) * 2019-08-28 2022-04-28 스타파마 피티와이 리미티드 표적화된 덴드리머 접합체
CA3152111A1 (en) * 2019-09-26 2021-04-01 David James Owen Therapeutic dendrimer
WO2021213492A1 (zh) * 2020-04-24 2021-10-28 上海森辉医药有限公司 一类载药的大分子及其制备方法
KR20230065935A (ko) * 2020-06-03 2023-05-12 스타파마 피티와이 리미티드 치료적 접합체
CN116133693A (zh) * 2020-08-25 2023-05-16 上海森辉医药有限公司 载药的大分子及其制备方法
EP4203968A1 (en) * 2020-08-31 2023-07-05 Starpharma Pty Limited Dendrimer-drug conjugate
US11331267B2 (en) * 2020-09-24 2022-05-17 Ocular Therapeutix, Inc. Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US7261875B2 (en) * 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
CN101102787A (zh) * 2004-08-09 2008-01-09 艾丽奥斯生物制药有限公司 合成的超糖基化、抗蛋白酶的多肽变体、口服制剂及其使用方法
CA2636599C (en) 2006-01-20 2014-07-15 Starpharma Pty Limited Modified macromolecule
CN101002945B (zh) * 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
DK2052011T3 (da) * 2006-08-11 2020-12-07 Starpharma Pty Ltd Målrettet polylysin-dendrimer-terapeutisk stof
DK2306986T3 (en) 2008-06-26 2018-06-18 Prolynx Llc PRODRUGS AND PHARMACEUTICAL Macromolecule Conjugates with Controlled Drug Release Rates
WO2011072290A2 (en) * 2009-12-11 2011-06-16 The Regents Of The University Of Michigan Targeted dendrimer-drug conjugates
WO2011140393A1 (en) 2010-05-05 2011-11-10 Prolynx Llc Controlled release from macromolecular conjugates
WO2011140376A1 (en) 2010-05-05 2011-11-10 Prolynx Llc Controlled drug release from dendrimers
WO2011140392A1 (en) 2010-05-05 2011-11-10 Prolynx Llc Controlled drug release from solid supports

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117164357A (zh) * 2023-01-03 2023-12-05 广东捷成科创电子股份有限公司 一种五元系大功率型压电陶瓷材料及其制备方法

Also Published As

Publication number Publication date
SI2729179T1 (sl) 2021-01-29
JP2014520105A (ja) 2014-08-21
JP6158177B2 (ja) 2017-07-05
PT2729179T (pt) 2020-11-25
HUE052285T2 (hu) 2021-04-28
AU2012267200A1 (en) 2013-05-09
WO2012167309A1 (en) 2012-12-13
CN110124051B (zh) 2022-10-21
CN103796684A (zh) 2014-05-14
KR20140041678A (ko) 2014-04-04
BR112013031556A2 (pt) 2017-08-29
CA2837979A1 (en) 2012-12-13
EP2729179B1 (en) 2020-09-23
US20140171375A1 (en) 2014-06-19
DK2729179T3 (da) 2020-12-21
EP2729179A4 (en) 2015-01-28
US20170354739A1 (en) 2017-12-14
CN110124051A (zh) 2019-08-16
EP2729179A1 (en) 2014-05-14
US9744246B2 (en) 2017-08-29
BR112013031556B1 (pt) 2022-03-29
US10265409B2 (en) 2019-04-23
CA2837979C (en) 2021-03-30
HRP20201998T1 (hr) 2021-02-05
LT2729179T (lt) 2020-12-28
PL2729179T3 (pl) 2021-07-19
ES2834992T3 (es) 2021-06-21
AU2012267200B2 (en) 2016-02-25
KR101941318B1 (ko) 2019-01-22
HK1198356A1 (en) 2015-04-10
CN103796684B (zh) 2019-06-25

Similar Documents

Publication Publication Date Title
IN2014DN00101A (pt)
MX2019000566A (es) Suministro mediado por ve de conjugados de proteína de enlace-molécula pequeña.
MX370543B (es) Profarmacos neutralizantes del factor de crecimiento endotelial vascular para el tratamiento de afecciones oculares.
WO2017044894A3 (en) Cartilage-homing peptides
MX348983B (es) Profarmacos que comprenden un conjugado de conector de exendina.
WO2016004048A3 (en) Targeted conjugates and particles and formulations thereof
EP4253395A3 (en) Processes for the preparation of carbohydrate conjugated rna agents
WO2014205317A3 (en) Cyclic peptides as protein targeting agents
WO2012075086A3 (en) Fabric care composition
WO2013019658A3 (en) Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents
MX2013001677A (es) Formulaciones estables de linaclotida.
IN2012DN02736A (pt)
SG194175A1 (en) Polymer conjugated prostaglandin analogues
WO2013040242A3 (en) Dermal filler compositions for fine line treatment
WO2011057225A3 (en) Self-assembled particles from zwitterionic polymers and related methods
IN2014DN08299A (pt)
WO2012174158A3 (en) Administration of benzodiazepine
MX2014004196A (es) Citramida de rasagilina.
JO3385B1 (ar) عقار أولي معتمد على جليكول عديد إثيلين من أدرينومدالين واستخدامه
EP2574170A4 (en) IMMUNOSTIMULATORY AND VACCINE COMPOSITIONS
GEP20166450B (en) Cyclic n,n'-diarylthioureas and n,n'-diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same
WO2012101653A3 (en) Modified release pharmaceutical compositions memantine
IN2014MN02236A (pt)
WO2012053013A3 (en) Pharmaceutical compositions of anti-acne agents
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib